NeuroSense Therapeutics Warrant
NRSNW
4 hedge funds and large institutions have $107K invested in NeuroSense Therapeutics Warrant in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more capital invested
Capital invested by funds: $53.5K → $107K (+$53.6K)
0.27% more ownership
Funds ownership: 2.63% → 2.9% (+0.27%)
0% more funds holding
Funds holding: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$10.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$606 |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$128 |
| 3 |
CS
Clear Street
New York
|
-$40 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Hudson Bay Capital Management
Stamford,
Connecticut
| $45K | – | – | – |
|
|
WAM
2
Warberg Asset Management
Winnetka,
Illinois
| $30.3K | -$606 | -1,903 | -2% |
|
|
CS
3
Clear Street
New York
| $22.1K | -$40 | -125 | -0.2% |
|
|
4
Citadel Advisors
Miami,
Florida
| $9.78K | +$10.4K | +32,611 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| – | -$128 | -798 | Closed |
|
NRSNW Hedge Fund Activity: Q1 2023 in Review
4 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q1 2023, worth a combined $107K — up 100% from $53.5K a quarter earlier.
Fund positioning in NRSNW was balanced in Q1 2023: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $10.4K. The largest seller was Warberg Asset Management, cutting an estimated $606.
- 4 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $107K of NeuroSense Therapeutics Warrant stock for Q1 2023, up 100% quarter-over-quarter.
- 1 fund opened new NeuroSense Therapeutics Warrant positions in Q1 2023 and 1 closed out, a net change of 0 holders.
- The largest NeuroSense Therapeutics Warrant buyer in Q1 2023 was Citadel Advisors, an estimated $10.4K added.
- The largest NeuroSense Therapeutics Warrant seller in Q1 2023 was Warberg Asset Management, an estimated $606 sold.
Based on aggregated 13F filings for Q1 2023.